288 related articles for article (PubMed ID: 11558856)
21. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
Ruilope LM; Simpson RL; Toh J; Arcuri KE; Goldberg AI; Sweet CS
Blood Press; 1996 Jan; 5(1):32-40. PubMed ID: 8777471
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S; Williams D; Chrysant SG; Marbury TC; Neutel J
J Clin Hypertens (Greenwich); 2001; 3(5):283-91, 318. PubMed ID: 11588406
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension.
Flack JM; Saunders E; Gradman A; Kraus WE; Lester FM; Pratt JH; Alderman M; Green S; Vargas R; Espenshade M; Ceesay P; Alexander J; Goldberg A;
Clin Ther; 2001 Aug; 23(8):1193-208. PubMed ID: 11558858
[TBL] [Abstract][Full Text] [Related]
25. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
27. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Pool JL; Glazer R; Chiang YT; Gatlin M
J Hum Hypertens; 1999 Apr; 13(4):275-81. PubMed ID: 10333347
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of valsartan in patients aged > or =65 years with systolic hypertension.
Neutel JM; Bedigian MP
Clin Ther; 2000 Aug; 22(8):961-9. PubMed ID: 10972632
[TBL] [Abstract][Full Text] [Related]
29. A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.
Bavanandan S; Morad Z; Ismail O; Chandran A; Thayaparan T; Singaraveloo M
Med J Malaysia; 2005 Jun; 60(2):158-62. PubMed ID: 16114156
[TBL] [Abstract][Full Text] [Related]
30. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
32. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
Lee HY; Kim SY; Choi KJ; Yoo BS; Cha DH; Jung HO; Ryu DR; Choi JH; Lee KJ; Park TH; Oh JH; Kim SM; Choi JY; Kim KH; Shim J; Kim WS; Choi SW; Park DG; Song PS; Hong TJ; Rhee MY; Rha SW; Park SW
Clin Ther; 2017 Dec; 39(12):2366-2379. PubMed ID: 29150250
[TBL] [Abstract][Full Text] [Related]
35. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
[TBL] [Abstract][Full Text] [Related]
36. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
Oparil S; Dyke S; Harris F; Kief J; James D; Hester A; Fitzsimmons S
Clin Ther; 1996; 18(5):797-810. PubMed ID: 8930424
[TBL] [Abstract][Full Text] [Related]
38. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
Germino FW
Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE;
Clin Ther; 2003 May; 25(5):1469-89. PubMed ID: 12867222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
